Extracellular secretion of a recombinant therapeutic peptide by Bacillus halodurans utilizing a modified flagellin type III secretion system
2011

Improving Peptide Production in Bacillus halodurans

publication Evidence: moderate

Author Information

Author(s): Berger Eldie, Crampton Michael C, Nxumalo Nolwandle P, Louw Maureen E

Primary Institution: CSIR Biosciences

Hypothesis

Can the type III secretion system of Bacillus halodurans be modified to enhance the secretion of therapeutic peptides?

Conclusion

The modified type III secretion system of Bacillus halodurans successfully increased the secretion of the therapeutic peptide Enfuvirtide.

Supporting Evidence

  • Strain B. halodurans BhFDL05S showed a 10-fold increase in peptide secretion after gene inactivation.
  • Further optimization with expression vector pNW33N led to a 3.5-fold increase in peptide secretion.
  • Enfuvirtide was chosen as a model system due to its complex chemical synthesis process.

Takeaway

Scientists made changes to a bacteria to help it produce a medicine better and faster. This could help make the medicine cheaper.

Methodology

The study involved modifying the flagellin type III secretion system in Bacillus halodurans and evaluating the secretion of the therapeutic peptide Enfuvirtide.

Limitations

The study primarily focused on shake flask studies, which may not fully represent industrial fermentation conditions.

Digital Object Identifier (DOI)

10.1186/1475-2859-10-62

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication